Serum Aluminum Concentration of Pediatric Patients Receiving Long-Term Parenteral Nutrition
Aluminum Contamination of Parenteral Nutrition
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Serum Aluminum Concentration of Pediatric Patients Receiving Long-Term Parenteral Nutrition: Is There a Problem in Canada?|
- serum aluminum concentration [ Time Frame: 5 months ]A 4 ml blood sample will be obtained from each control subject when they are giving blood for routine clinbical purposes. These subjects will be recruited from in-patient wards or ambulatory clinics. The aluminum content of samples (plasma aluminum concentration) will be determined by high resolution sector field inductively coupled mass spectrometry (HR-SF-ICP-MS). The accuracy and precision of the instrument used to determine aluminum concentration is measured using external and internal standards. Accuracy and precision was last measured at ± 0.5 to 2.5% and 5 to 10% respectively
Biospecimen Retention: None Retained
|Study Start Date:||June 2011|
|Study Completion Date:||December 2012|
|Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
|On long-term PN|
|Never been on TPN|
Aluminum contamination of parenteral nutrition (PN) solutions has been a concern for decades because of its link to metabolic bone disease (MBD) due to it's high aluminum content. Currently in the United States, FDA regulations are in place to protect American patients on PN from the effects of aluminum (AL) toxicity. Despite these regulations, pediatric patients on PN are still receiving higher than recommended AL intakes from PN.
Unlike the United States, there are no regulations governing AL content of or intakes from PN solutions in Canada. Consequently, the investigators are unaware of the AL content of the various PN solutions given to our patients. The investigators (the authors) have observed that a significant number of our patients on long-term PN (Home PN), have MBD. Some of our patients have also had bone fractures. The investigators have also observed alteration in calcium and phosphate concentrations as well as suppressed PTH. In an effort to understand the etiology of the MBD the investigators have measured serum AL concentrations in our patients and have found them to be high; between 900 - 2000 nmol/L compared to 0 to 220 nmol/L reported in healthy adults. This has led us to believe that there is a significant problem of AL contamination in PN solutions in Canada. Because the investigators are unable to obtain information on the AL content of the various PN solutions from the PN suppliers, the investigators have decided to report on the serum AL concentrations of our patients as well as the AL concentration of a random sample of PN solutions provided to patients. Plasma aluminum concentrations have already been analyzed in each of the cases. Blood was drawn for routine clinical monitoring on each subject after they had been on PN for six weeks or more.
This is the first step towards raising awareness of the potential problem. It is our hope that this will provide initial evidence to help guide Health Canada's decision regarding regulations on AL content in PN solutions in Canada.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01371123
|The Hospital for Sick Children|
|Toronto, Ontario, Canada, M5G 1X8|
|Principal Investigator:||Glenda Courtney-Martin, MSc, PhD, RD||The Hospital for Sick Children|